In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Heart failure and diabetes: a treacherous combination
Session

Event : ESC Congress 2017

Topic : Chronic Heart Failure - Other

  • Session type : Advances in Science
  • Date : 29 August 2017
  • Time : 08:30 - 10:00

5 presentations in this session

State of the Art: glucose-lowering drugs and cardiovascular outcomes

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : S Anker (Berlin,DE)

Heart failure with mid range ejection fraction, characteristics and prognosis in patients with and without type 2 diabetes

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : I Johansson (Hamilton,CA)

How does diabetes affect iron status in patients with heart failure?

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : M Drozd (Wroclaw,PL)

Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : D Fitchett (Toronto,CA)

Heart failure and diabetes: lessons from the ESC long-term registry

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : O Chioncel (Bucuresti,RO)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are